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Abstract
Objective To determine if an intervention consisting of telemonitoring
and supervision by usual primary care clinicians of home self measured
blood pressure and optional patient decision support leads to clinically
important reductions in daytime systolic and diastolic ambulatory blood
pressure in patients with uncontrolled blood pressure.
Design Multicentre randomised controlled trial.
Setting 20 primary care practices in south east Scotland.
Participants 401 people aged 29-95 years with uncontrolled blood
pressure (mean daytime ambulatory measurement ≥135/85 mm Hg but
≤210/135 mm Hg).
Intervention Self measurement and transmission of blood pressure
readings to a secure website for review by the attending nurse or doctor
and participant, with optional automated patient decision support by text
or email for six months.
Main outcomemeasures Blinded assessment of mean daytime systolic
ambulatory blood pressure six months after randomisation.
Results 200 participants were randomised to the intervention and 201
to usual care; primary outcome data were available for 90% of
participants (182 and 177, respectively). The mean difference in daytime
systolic ambulatory blood pressure adjusted for baseline andminimisation
factors between intervention and usual care was 4.3 mm Hg (95%
confidence interval 2.0 to 6.5; P=0.0002) and for daytime diastolic
ambulatory blood pressure was 2.3 mm Hg (0.9 to 3.6; P=0.001), with
higher values in the usual care group. The intervention was associated
with amean increase of one general practitioner (95% confidence interval
0.5 to 1.6; P=0.0002) and 0.6 (0.1 to 1.0; P=0.01) practice nurse
consultations during the course of the study.
Conclusions Supported self monitoring by telemonitoring is an effective
method for achieving clinically important reductions in blood pressure
in patients with uncontrolled hypertension in primary care settings.
However, it was associated with increase in use of National Health
Service resources. Further research is required to determine if the
reduction in blood pressure is maintained in the longer term and if the
intervention is cost effective.
Trial registration Current Controlled Trials ISRCTN72614272.
Introduction
Raised blood pressure is one of the most important risk factors
for ischaemic heart disease and stroke, and globally is estimated
to contribute to 7.6 million premature deaths annually.1Despite
the availability of effective drugs, the control of blood pressure
typically remains poor in routine clinical settings.2 The reasons
for this include infrequent monitoring of blood pressure,3
reluctance by doctors to intensify drug treatment,4 and poor
treatment adherence by patients.5 Self monitoring is a potentially
attractive way of tackling the first problem; however, several
trials have shown that isolated patient self monitoring has, if
any, a small effect on improving blood pressure.6 7
Telemonitoring has been advocated as an enhancement to self
monitoring, where readings taken by the patient are transmitted
automatically, usually by mobile phone, to a website, enabling
patients to share their readings with healthcare professionals in
real time.6 Patients and clinical staff have the advantage of access
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to multiple readings taken throughout the day both at home and
at work. Systematic reviews8 9 on the use of telemonitoring in
the management of hypertension have identified a relatively
small body of studies—some methodologically weak—that
have been specifically targeted at people with high blood
pressure. Other larger studies that have included telemonitoring
to manage blood pressure have concerned additional
interventions such as self management10 or pharmacist
intervention,11 or included some people who did not have high
blood pressure.12 13 Few studies have used ambulatory blood
pressure monitoring, the accepted ideal measure,14 and as a result
have included people with “white coat” hypertension or used
unblinded outcome measures possibly leading to exaggerated
treatment effects. These studies are therefore difficult to
interpret, hence the systematic reviews have highlighted the
need for further methodologically robust studies of low cost
telemonitoring interventions undertaken in routine clinical care
using blood pressure measured by ambulatory blood pressure
monitoring as the main outcome.6 9
We determined whether using a six month intervention of
telemonitored support of self monitoring in patients with
uncontrolled blood pressure within the context of their usual
primary care services, with optional patient decision support
and appropriate supervision from primary care clinicians, could
lead to clinically important reductions in blood pressure. We
also determined the impact of such telemonitored support on
use of health service resources.
Methods
During 2009-11 we conducted a pragmatic parallel group
randomised controlled trial with blinded outcome assessment
and analysis.
We identified potentially eligible participants from electronic
searches of clinical record systems in 20 socioeconomically
diverse general practices in south east Scotland, based on the
Scottish index of multiple deprivation,15 and recruited
participants between February 2009 and October 2010. We
invited those aged 18 or more with a diagnosis of hypertension
whose last surgery blood pressure measurement was >145 mm
Hg systolic or >85 mm Hg diastolic to attend for a screening
assessment. Exclusion criteria were inability to consent, atrial
fibrillation, being on the stroke or diabetes registers (as these
participants would be invited to other trials in our portfolio of
trials investigating the role of telemonitoring in the management
of long term conditions), treatment for a cardiac event or other
life threatening illness in the past six months, major surgery
within the past three months, renal failure, or hypertension
managed in secondary care.
Recruitment of participants and baseline
assessment
Potentially eligible participants were invited to undertake
daytime ambulatory blood pressure monitoring (90207 ABP
Monitors; Spacelabs Healthcare,Washington).16Readings were
taken every 20 minutes for 14 hours. As experience in our pilot
work suggested that some participants might be unwilling to
undergo a second ambulatory blood pressure monitoring at the
end of the study, we also measured blood pressure electronically
in the clinic on both arms, initially using the Stabil-O-Graph
(IEM, Germany)17 device with an appropriately sized cuff and
after a five minute rest, and then twice more using the
ambulatory blood pressure monitor. We then fitted the monitor
on the non-dominant arm or, if there was a difference of >20/10
mm Hg between the two arms, the arm with the higher systolic
reading. Participants were included if their mean daytime
ambulatory blood pressure was ≥135/85 mm Hg but ≤210/135
mm Hg.
Outcome measures
The primary outcome was mean daytime ambulatory systolic
blood pressure at six months post-randomisation.
Secondary outcomes were mean daytime ambulatory systolic
and diastolic blood pressure (mean of the second two out of
three office readings each). In addition we recorded details of
antihypertensive drugs prescribed and use of National Health
Service resources. Two further planned secondary outcome
measures were not measured or reported: grip strength was not
measured in the trial owing to problems with equipment, and a
questionnaire on self reported frequency of exercise18was found
to be too complex or deemed inappropriate bymany participants
and as a result was so poorly completed that it was not
considered appropriate to report.
Randomisation and protection against bias
The Edinburgh Clinical Trials Unit independently randomised
participants to intervention or usual care arms in a 1:1 ratio
using a secure system. The computer generated allocation
sequence was accessed via the internet and ensured allocation
concealment. Minimisation was undertaken on the basis of age,
sex, general practice, use of three or more antihypertensives,
and current use of blood pressure self monitoring. Because
simple minimisation within centres can lead to alternation of
treatment allocation and potential loss of allocation concealment,
we also incorporated a degree of random allocation. As the
intervention comprised providing telemonitoring equipment,
neither participants nor investigators could be masked to group
assignment. The main outcome measure was machine derived,
and research nurses blinded to allocation undertook the
assessment of other outcomes, thereby minimising the risk of
bias.
Trial procedures
Telemonitoring
Research nurses gave participants assigned to the intervention
a 20 minute training session on how to use the telemonitoring
equipment. Participants were asked to monitor their own blood
pressure twice each morning and twice each evening for the
first week and then at least weekly thereafter or as often as they
wished. They used a validated automated sphygmomanometer
(Stabil-O-Graph mobil; IEM, Stuttgart, Germany).17 This was
linked by a short range wireless connection to a mobile phone,
which automatically transmitted readings to a central server
managed by IEM. Participants and clinicians could log on to a
website to see the data, and automated SMS texts or emails
could be sent to participants with feedback on their blood
pressure control (see the box for a fuller desription of the
process). Participants could contact their clinicians if they were
concerned about their blood pressure control and clinicians
could contact the participants if needed to arrange modification
of therapy. The target home monitored blood pressure was
<135/85 mm Hg based on contemporaneous UK guidelines,19
subsequently endorsed by the National Institute for Health and
Clinical Excellence.20
Participants allocated to both the intervention and the usual care
group were told that the ambulatory blood pressure showed that
their blood pressure was uncontrolled. Participants allocated to
the usual care group were advised that they should see their
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Telemonitoring intervention (see supplemental file for illustrations)
The intervention
The practices and participants were asked to use a system that comprised a validated electronic home blood pressure monitor and mobile
phone technology. The phone technology enabled the transfer of blood pressure readings via SMS to a secure website that was accessible
to the users and their doctor or nurse, and also provided automated feedback to the patient. The blood pressure monitor linked to a mobile
phone wirelessly, via Bluetooth. The intervention comprised several components:
Home blood pressure monitoring—participants were asked to record their blood pressure as agreed with the healthcare team, or more often
as they wished. Guidance was initially to record blood pressure twice in the morning and twice in the evening for a week in line with the
European guideline on blood pressure monitoring,47 to build a baseline average. Thereafter they were asked to take weekly measurements,
preferably at different times of day if their average blood pressure was within the recommended range. If, however, they had made any
change to lifestyle or drugs that would impact on their blood pressure, they were asked to measure their blood pressure for a more intensive
period of monitoring to allow the rolling average to change and more quickly assess the effect.
Transmission of data—this simply required the phone to be switched on and to have a signal when the blood pressure measurement was
taken. Participants just had to apply the cuff and press a button on the blood pressure monitor. The reading and transmission occurred
automatically. Mobile phone problems did not lead to loss of data because all readings were stored in the monitor and any readings that did
not get transmitted were sent when the next reading was taken.
Feedback to patient participants (closed loop feedback)—in addition to optionally accessing their blood pressure record online, participants
could also opt to receive reports via text message or email. These messages gave advice on the current status of the participants’ blood
pressure, based on the average of the last 10 readings, and whether they should contact their doctor or nurse. Reports were generated
every 10 readings or weekly, whichever was sooner, with a reminder to check blood pressure if this had not been done. These reports could
reassure participants that their average blood pressure was within target (≤135/85 mm Hg) or tell them that their blood pressure average
was improved from the last report but not yet to target and to maintain current therapy, or that their blood pressure was not at target and
that they should contact their clinician. If an individual blood pressure reading was high (>220/120 mm Hg), an immediate text or email report
was generated, reinforcing the written advice in the patient information leaflet to rest for 30 minutes, check again, and contact the practice
if blood pressure remained high.
Sharing readings with healthcare team—members of the healthcare team were able to access the records of their patients online via a
secure login to a summary screen, which listed their patients, their average blood pressure over the last 10 readings, and the date of their
last reading. Average blood pressures outside the recommended limits (set at 135/85 mm Hg for the study) were highlighted. Clicking on
the name of individual patients led to lists or graphs of all their readings. Clinicians could then check their patients’ electronic general
practitioner record to see if there had been recent advice about drug or lifestyle change and, if not, could contact the patient to make a
change. Clinicians were recommended to check the website weekly, but they could choose the frequency of log on.
Usual care
Participants allocated to the usual care group were asked to continue to attend the practice for blood pressure checks according to the usual
routine of the practice. If they were already monitoring their blood pressure at home they were not discouraged.
All participants
The general practitioner or practice nurse was informed that the ambulatory monitoring used to screen for eligibility for the current trial had
shown that their average blood pressure for all participants was above the target range, but they were not given the actual reading. All
participants were given an information pack containing a range of publicly available leaflets on the management of hypertension and lifestyle
modification.
doctor or practice nurse for further management. Subsequently
they received standard care for hypertension from their doctor
or nurse who were asked to aim for a target surgery blood
pressure of <140/90 mmHg based on the current UK guidelines
for that period.19
Clinical care in both groups
All participating doctors and nurses were already using a local
guideline for hypertension management derived from national
hypertension guidelines19 but were given additional guidance
on timelines for escalating therapy. Participating practices were
offered an educational session with a member of the research
team (PLP) who specialises in the management of hypertension.
All participants received written information outlining drug and
non-drug interventions to reduce blood pressure. Members of
the research team did not provide any ongoing monitoring or
clinical care.
Data collection
Research nurses who had not been involved in recruitment
undertook the end of study visit in the general practice surgery.
Participants were asked by letter before the appointment not to
reveal their allocation. Baseline measures were repeated. Those
participants who were not prepared to undertake ambulatory
blood pressure had three measures taken in the doctor’s surgery
and the average of the second two measures were recorded.
From the electronic health record the research nurses obtained
information on antihypertensives prescribed, attendances, and
telephone contacts with doctors, practice nurses, district nurses,
and hospital and out of hours contacts.
Sample size calculations
The sample size was based on the mean daytime systolic
ambulatory blood pressure (142 mm Hg) and its standard
deviation (14 mm Hg) measured in a similar group of
participants at the end of our pilot work. The likely effect size
was based on a systematic review of non-drug interventions to
reduce hypertension in which there was an average reduction
of 4.5 mm Hg in systolic blood pressure.21 Such a reduction is
considered clinically significant in that if it were to be sustained
over 10 years it would be expected to lead to a greater than 15%
reduction in risk of stroke and a greater than 10% reduction in
risk of coronary heart disease.22 To have 80% power to identify
a difference between telemonitoring and usual care of 4.5 mm
Hg in systolic ambulatory blood pressure in a two tailed test
with α set at 0.05, we needed 155 participants in each arm.
Allowing for a 20% dropout, we aimed to recruit a total of 400
participants.
Data analysis
We used analysis of covariance to analyse the primary and
secondary outcomes, adjusting for the baseline value and the
minimisation factors (age, sex, general practice, use of three or
more hypertension drugs, history of self monitoring blood
pressure). We analysed the participants’ data on an intention to
treat basis. In the primary analysis we excluded participants
with missing outcome data. Adjusted analyses and analyses
adjusted only for baseline are presented. We assessed all
modelling assumptions that were deemed to be valid. Where
relevant, we investigated the effect of excluding outlying data
points and were unable to identify any important differences
(data not shown).
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We compared the change in hypertension drug status using a χ2
test and the changes in defined daily doses23 of blood pressure
drugs using a χ2 test for trend.
The predefined subgroups for the primary outcome were sex,
age group, and socioeconomic status, defined using fifths of the
national area based Scottish index of multiple deprivation
score.15 Subgroup analyses were performed by adding the
interaction between the subgroup variable and randomised
treatment into the analysis of covariance model.
We measured quality of life using index scores generated from
standard algorithms for the EuroQol-5D (EQ-5D).24 The EQ-5D
index scores were tested using non-parametric bootstrap of
differences in means between trial arms reporting confidence
intervals and P values (two tailed) for each, with significance
set at the 5% level.
As a secondary analysis we usedmultiple imputation by chained
equations25 to create 10 imputed datasets by imputing incomplete
variables under fully conditional specification. This was based
on age, sex, body mass index, blood pressure (systolic and
diastolic), number of hypertension drugs, cholesterol level,
exhaled percentage of carbon monoxide, HbA1c level, EQ-5D
responses, and all variables for use of healthcare resources.
Calculations were undertaken in STATA 12 using the user
written “mi ice” command. We imputed normally distributed
variables (including primary outcome data) using multiple
regression by ordinary least squares, ordered categorical
variables using ordinal logistic regression, and other non-normal
variables using predictive mean matching. We then estimated
model variables using the respective regression techniques
described. These estimates and their standard errors were
combined using Rubin’s rules26 within Stata’s “mi” suit.
Economic evaluation
A full description of the analysis of resource use and costs are
presented elsewhere27; however, we searched the general
practitioner records to establish the use of NHS resources
(telephone calls, surgery and home visits carried out by general
practitioners, practice nurses, and district nurses, and attendance
at out of hours service, accident and emergency, and hospital
admission) and data on antihypertensive drug use. Unit costs
were taken from recognised national sources.28-32
The health economic analysis was performed using SAS
statistical software (version 9.2), Minitab statistical software
(version 16), Stata 12, and Microsoft Excel 2003.
Qualitative process evaluation
A full description of the process analysis is presented
elsewhere.33 Participating patients, doctors, and nurses taking
part in the study were approached and, using semistructured
interviews, asked about their experience of taking part in the
intervention. All interviews were recorded and transcribed. They
were analysed thematically, with initial codes and themes
identified inductively from the data. We used constant
comparison34 to ensure consistency in coding, and we sought
negative cases for each coding category. Two researchers
checked and iteratively refined the coding using paired analysis
of transcripts and these were presented to a meeting of
participant patients and clinicians to elicit their views on the
analysis.
Results
Participants were recruited from practices representing a range
of socioeconomic diversity, including practices with postcodes
in the fifth most deprived and second most affluent areas in
Lothian, Scotland. Four hundred and one participants from 20
general practices (range 5-45 participants per practice) were
randomly assigned to the monitored (n=200) or usual care
(n=201) group (fig 1⇓). Of these, 182 (91%) in the intervention
group and 177 (88%) in the usual care group undertook daytime
ambulatory blood pressure monitoring for the primary outcome.
In total, 195 (98%) in the intervention group and 185 (93%) in
the usual care group attended the follow-up visits at six months
and provided some data. Of those not providing complete data,
11 participants in the intervention group and eight in the usual
care group declined to have repeat ambulatory blood pressure
monitoring; three for medical reasons and 16 because they felt
the procedure too uncomfortable. Of the remainder, a further
six participants in the intervention group and 14 in the usual
care group were either lost to follow-up or withdrew consent,
and one in the intervention group and two in the usual care
group died before follow-up. Around half of the participants in
the intervention group asked for text or email alerts at some
point, although a small number subsequently asked for them to
be switched off.
Baseline characteristics
Table 1⇓ shows the baseline characteristics of the 401
participants and the characteristics of those who did not provide
primary outcome data. The trial arms were well balanced.
Primary outcome
The mean daytime systolic ambulatory blood pressure fell in
both groups, from 146.0 mm Hg to 140.0 mm Hg in the
telemonitoring arm and from 146.5 mm Hg to 144.3 mm Hg in
the usual care arm (table 2⇓. The difference between the two
arms at six months (that is, usual care minus intervention) was
4.3 mm Hg (95% confidence interval 2.0 to 6.5; P=0.0002),
adjusted for baseline mean daytime systolic ambulatory blood
pressure and minimisation factors. The treatment effect was
similar for age, sex, and fifth of deprivation index (fig 2⇓).
In a sensitivity analysis using multiple imputation to allow for
missing outcome data, the mean difference was 4.5 mm Hg
(95% confidence interval 2.5 to 6.6; P<0.001). In addition we
carried out a retrospective cluster analysis. The intraclass
correlation coefficient was 0.02, and the point estimate after
adjustment for clustering was 4.06 (95% confidence interval
1.43 to 6.68), P=0.0034. There was no evidence of between
centre heterogeneity.
Secondary outcomes
Themean daytime diastolic ambulatory blood pressure also fell
in both arms (table 2), from 87.4 mm Hg to 83.4 mm Hg in the
telemonitoring arm and from 85.7 mm Hg to 84.3 mm Hg in
the usual care arm. The difference in mean daytime diastolic
ambulatory blood pressure at six months between the two arms
(usual care minus telemonitored) was 2.3 mm Hg (95%
confidence interval 0.9 to 3.6; P=0.001), adjusted for baseline
mean daytime diastolic ambulatory blood pressure and
minimisation factors.
The difference inmean surgerymeasured systolic blood pressure
at six months between the two groups (usual care minus
intervention) was 4.6 mm Hg (95% confidence interval 1.7 to
7.5; P=0.0017) and for surgerymeasured diastolic blood pressure
was 2.8 mm Hg (1.0 to 4.6; P=0.0021), adjusted for baseline
surgery blood pressure and minimisation factors (table 3⇓).
Intervention and usual care groups did not differ significantly
in the secondary outcome measures of self reported adherence
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to drugs, potential indicators of lifestyle adjustment (weight,
spot sodium:creatinine ratio, cholesterol level, HbA1c level),
self assessed therapy adherence, anxiety, health related quality
of life, or exercise tolerance (table 4⇓).
Number of drugs and defined daily dosage
At follow-up more participants were taking two or three
antihypertensive drugs compared with at baseline (fig 3⇓ and
table 5⇓). More participants in the telemonitoring arm than in
the usual care arm had an increase in the number of drugs
(P<0.001). There were increases in drug use across all the main
drug groups, with calcium antagonists showing the biggest rise
(table 6⇓).
In a retrospective comparison we found that the treatment
intensity in the telemonitoring group also increased, with 76
(39%) of participants in the telemonitoring group increasing
their defined daily dosage of antihypertensive drugs compared
with 22 (12%) of participants in the usual care group (P=0.0003).
Resource use
A full description of NHS resource use is presented elsewhere.27
After multiple imputation the mean NHS costs (excluding
hospital admissions) per patient over the six month intervention
period were significantly higher in the telemonitoring group
than in the usual care group, by approximately £109.32
($173.41; €130.24). The increase in costs was predominantly
driven by the estimated intervention costs (£70.77), including
monitor, mobile phone, and connection charges; server and web
hosting; and the time it took nurses to check the website weekly.
In addition significant increases in costs were associated with
participants in the telemonitoring group using on average one
additional general practitioner surgery consultation (£32.89),
half of a practice nurse surgery consultation (£5.86), and half
of a practice nurse telephone consultation (£2.57, table 7⇓).
Compliance with the intervention
Participants in the telemonitoring arm took amedian of 76 blood
pressure readings, and 178 (89%) completed more than 90% of
the expected minimum number of readings during the trial. Five
people requested to stop using the homemonitor of whom three
subsequently withdrew (with the other two continuing until the
end of the trial).
Adverse events
In total, 43 adverse events were recorded. One death occurred
in the intervention group and two in the usual care group, none
of which were thought to be related to blood pressure. The other
events included three people who reported anxiety as a result
of self monitoring, one who had a fall, and two who fainted
(which may have been related to blood pressure control), and
six seen in hospital because of cardiovascular problems (two
atrial fibrillation, two chest pain, two very high blood pressure).
In addition, one patient had a rash thought to be due to
antihypertensive drug therapy and one developed hyperkalaemia
secondary to dehydration and a viral illness but that was possibly
exacerbated by antihypertensive drug therapy. The remainder
had hospital admissions thought to be unrelated to blood
pressure or the intervention. Apart from the three who had
become anxious as a result of self monitoring, adverse events
were evenly distributed between the groups.
Qualitative process analysis
A full description of the process analysis is presented
elsewhere.33 Interviews were conducted with 11 nurses, nine
doctors, and 25 patient participants, representing a maximum
variation sample of patients based on age, sex, and deprivation
status of the practice. Patients were generally positive about the
intervention, although it was associated with anxiety in a small
number of cases. Patient participants and clinicians admitted
that before the intervention they were reluctant to increase drugs
based on single blood pressure measurements taken in the
surgery. Patient participants thought that the process improved
access to clinicians and to reliable shared data, around which it
was possible to have more equitable and informed discussions.
Telemonitoring measurements based on multiple readings were
perceived to be more accurate, be difficult to ignore, and lead
to action. In some cases the alerts warning of inadequate blood
pressure control were considered intrusive and irritating,
especially when the blood pressure drug had recently been
adjusted or the blood pressure was only 1 or 2 mm Hg above
target, and some asked for these to be switched off, although
others believed that they kept them engaged with the process.
Clinicians noted a perceived increase in workload as a result of
the intervention, partly due to lack of integration with main
electronic health records and routine working processes, which
also meant that the online blood pressure record was not easily
accessed by all members of the healthcare team. Nurses reported
that some patients did not respond to requests to attend the
surgery, and accessing patients by phone was also sometimes
problematical. On the few occasions when email was used for
communication this was considered to work well. Both patient
participants and clinicians thought that over the long term, with
improved integration into normal practice systems the
intervention would eventually reduce the need for visits to the
surgery.
Discussion
In this pragmatic35 community based trial we found that a
relatively brief period of management of hypertension by home
self measurement by patients with telemonitoring delivered by
practice nurses and general practitioners was more effective in
lowering daytime systolic and diastolic ambulatory blood
pressure than was usual care. The average reduction in daytime
systolic ambulatory blood pressure of 4.3 mm Hg over and
above the improvements seen in the usual care group was
impressive, particularly since the UK’s Quality and Outcomes
Framework36 financially incentivises general practitioners to
achieve strict blood pressure control targets. Most participants
in this study had been selected from a cohort for whom—despite
these incentives—this target had not been reached. This study
was not powered to detect changes in cardiovascular outcomes;
however, based on previous studies, if sustained, blood pressure
reductions of the magnitude achieved in this study would be
expected to lead to a greater than 15% reduction in risk of stroke
and a greater than 10% reduction in risk of coronary heart
disease.22
The total cost of the intervention over the six month period was
£109.32 or approximately £25.56/mm Hg of systolic pressure
lowered. This figure includes the costs of the equipment and
training. However, there was a small increase in consultations
with general practitioners and nurses. Some additional visits
were inevitable—for example, to check renal function after
starting treatment. Despite increased use of telephone
management, duplication of effort which often happens in the
introductory phase of new technologies may have played a part,37
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and other similar studies have found no increased use of clinical
services.10 38 Patient participants and clinicians both thought that
efficiencies in direct professional-patient contact time may, in
time, be realised once these newways of working are established
and there is better integration of telehealth data within practice
computer systems and the use of asynchronous methods of
communication such as email or webmail become more
prevalent. In addition, the costs, if blood pressure lowering were
to be sustained, are likely to be mitigated by prevention of
cardiovascular events in succeeding years. None the less, some
caution should be applied when considering rolling out
telemonitoring at scale based on these findings.
Strengths and limitations of this study
Unlike many other trials we applied no age limits (the oldest
participant was 95) and we did not exclude on the basis of
maximal treatment. We also recruited from practices caring for
patients from a wide socioeconomic profile. There was no
apparent impact on the effectiveness of the intervention in
relation to age, sex, or social deprivation, although the study
was not powered to detect subgroup effects. Our qualitative
research shows that patients were generally positive about the
intervention and complied with it well. Although a few people
did stop because of anxiety, there was no overall increase in
anxiety in the telemonitored group as measured by the hospital
anxiety and depression scale.39 Additionally, intensification of
treatment in the telemonitoring group did not seem to lead to a
reduction in quality of life. Improved quality of life, however,
has been found in other similar studies.38 40 We consider that
our findings are robust. Unlike most previous studies we used
the ideal method of ambulatory blood pressure monitoring at
baseline and for measuring the primary outcome. Thirty per
cent of participants whose last blood pressure reading in the
surgery was >145/85 mm Hg were found on ambulatory blood
pressure monitoring to have a blood pressure reading <135/85
mmHg andwere therefore not included. This therefore excluded
those with “white coat hypertension” and minimised the effect
that any possible “habituation” with self monitoring may have
had on electronic measurements. Although participants could
not be blinded to allocation, nurses involved in the follow-up
were blinded. Although 94% of participants attended follow-up,
the primary outcome was measured in 90% of participants as
some refused a second ambulatory blood pressure monitoring.
However, similar results were obtained for ambulatory blood
pressure monitoring and surgery measured blood pressure. It is
possible that those lost to follow-up affected the treatment effect
estimate. We found no significant difference in the baseline
values of those with and without primary outcome
measurements; however, we accept that the failure to identify
statistically significant differences may relate to the small
numbers of people without an outcome measure. An analysis
using multiple imputation of missing outcome data gave similar
results to the primary analysis excluding missing data and,
indeed, the primary analysis was the more conservative
approach. Randomisation was at the level of the participant.
Although this raises the possibility of clustering effects, the
numbers of study participants within each practice constituted
a tiny proportion of all such patients and the risk of significant
contamination is therefore small. A retrospective cluster analysis
showed a low intracluster correlation coefficient and did not
alter the outcome, suggesting that clustering did not have a
major effect. In this situation, a cluster randomised trial may
have been more open to bias than a randomised trial at
participant level.41 Indeed, the highlighting of poor blood
pressure control and treatment optimisation in the
non-intervention group may have led to an underestimate of the
intervention effect. Confidence intervals around the difference
in blood pressure suggested the effect could be as low as 2.0
mm Hg or slightly lower if clustering is taken into account.
However, pooled data from other trials and observational studies
estimated that even blood pressure reductions as low as a 2-3
mmHg difference can result in a reduction of the stroke rate by
6-12%.42 Our intervention ran for six months. It is unclear
whether a longer intervention may have shown similar, greater,
or lesser effects or if the impact would be sustained. One study10
showed a small increase in effect between six and 12 months
and another study, in which blood pressure was telemonitored
by a research nurse, found a sustained improvement at 18
months in a subgroup of participants with uncontrolled blood
pressure at baseline.13 Other studies have found worse control
with self monitoring.43 44 In these studies, however, participants
reduced their drug dose in response to the lower blood pressure
reading at home. In a complex intervention such as this that
involved self monitoring, telemonitoring, and a degree of
decision support through the feedback participants received, it
is difficult to be sure to what extent each of these components
contributed. Ameta-analysis of studies exploring the use of self
monitoring alone that have used ambulatory blood pressure as
an outcome showed no significant improvement in systolic
blood pressure.7 None the less, further research directly
comparing self monitoring alone with that supported by
telemonitoring should be considered in future.
Strengths andweaknesses in relation to other
studies
The major contribution of this study is to clearly establish that
telemonitored supported self monitoring is an effective tool that
can improve the management of objectively measured
hypertension within a usual care context without the addition
of extra services or new protocols. While there have been other
studies of telemonitoring alone in people with uncontrolled
blood pressure, whose primary endpoint was systolic blood
pressure measured by ambulatory blood pressure monitoring,
two were small single centre studies that ran for 12 weeks,45 46
and another study that showed no difference between
intervention and control at six months may have been
underpowered.38 A fourth trial, set in Italian primary care,
showed a significant improvement in the numbers of participants
achieving control of blood pressure but showed no overall
reduction in daytime ambulatory systolic blood pressure.40Those
using unblinded office results have beenmore positive, reporting
reductions of 5.64/2.78 mm Hg.8 Other, larger studies using
ambulatory monitoring have focused on people with diabetes
some of whom had normal blood pressure,12 or included complex
interventions of which telemonitoring was only a small
component. One study11 showed that a web based recording
system combined with encouragement to contact a clinician if
blood pressure was raised had a modest effect in controlling
blood pressure; however, this was enhanced by the addition of
an intensive pharmacist intervention. Another study10 also
showed that adding a drug self management plan to self
monitoring, with a monthly summary of results collected by
telemonitoring sent to the patient and the doctor by the research
team produced similar reductions in blood pressure to our study.
It is likely that the greater reduction in blood pressure in the
telemonitored arm was largely achieved by increased
prescribing. This has been found in other trials where
telemonitoring has been an integral component.8 9Other possible
contributing factors were the effect of self monitoring itself and
the impact of perceived surveillance on adherence to drugs and
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lifestyle advice. However, there was no evidence in this trial
that the intervention had influenced self reported adherence, or
measures indicative of behavioural change. Indeed, patients and
clinicians taking part in the embedded accompanying linked
qualitative study said that ready access to timely good quality
data indicative of high blood pressure had some impact in
overcoming what has been described as “therapeutic inertia.”4
Conclusion and implications
A recent systematic review and meta-analysis of home blood
pressuremonitoring described themanagement of blood pressure
generally to be “dismal.”6 The present trial, using rigorous
endpoints, showed that the use of supported telemonitoring of
home measured blood pressure in primary care produces
clinically important reductions in both daytime systolic and
diastolic ambulatory blood pressure in a group of patients with
uncontrolled blood pressure. However, supported telemonitoring
was associated with an increase in use of NHS resources. The
intervention was viewed positively by both clinicians and
patients and has the potential to be implemented in many
healthcare settings, which may be facilitated by improved
integration with existing primary care electronic health records.
However, before advocating rolling out this intervention at scale,
further research is required to determine if the reduction in blood
pressure achieved over six months is maintained in the longer
term and that it is cost effective.
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Tables
Table 1| Baseline characteristics for full dataset and for participants not providing primary outcome data. Values are numbers (percentages)
unless stated otherwise
Primary outcome data not providedPrimary outcome data provided
Variables
Usual care group
(n-24)
Monitored group
(n=18)Usual care group (n=201)Monitored group (n=200)
57.3 (12.8)60.6 (11.5)60.8 (10.7)60.5 (11.8)Mean (SD) age (years)
12 (50)9 (50)120 (60)117 (59)Men
History of blood pressure self monitoring:
16 (67)13 (72)126 (63)128 (64)Never
5 (21)4 (22)56 (28)56 (28)Occasionally
3 (13)1 (6)19 (9)16 (8)Regularly
30.7 (7.0)31.5 (5.6)30.2 (6.2)30.1 (5.7)Mean (SD) body mass index (kg/m2)
3 (13)2 (11)20 (10)23 (12)Smoker
32.5 (10.6)13.5 (9.2)14.9 (10.4)17.6 (9.2)Mean (SD) No of cigarettes/day
21 (88)16 (89)181 (90)177 (89)Non-smoker
17 (71)12 (67)159 (79)158 (79)Consumes alcohol
1.3 (0.6-3.4)1.5 (0.8-2.5)2.0 (0.7-4.0)1.7 (0.9-2.9)
Median (interquartile range) units of alcohol (10
mL)/day
7 (29)4 (22)41 (20)37 (19)Does not consume alcohol
1215Missing data
Exhaled carbon monoxide category (parts per million):
20 (83)16 (89)179 (89)177 (89)Non-smoker (1-6)
0 (0)0 (0)3 (1)0 (0)Light smoker (7-10)
2 (8)1 (6)11 (5)8 (4)Moderate smoker (11-20)
2 (8)1 (6)8 (4)15 (8)Heavy smoker (≥20)
5.7 (1.3)5.5 (0.7)5.3 (1.0)5.5 (1.0)Mean (SD) cholesterol level (mmol/L)
1085Missing data
39.5 (9.2)37.3 (4.9)37.7 (5.1)38.0 (6.3)Mean (SD) haemoglobin A1c level (mmol/mol)
1097Missing data
9.1 (6.7)10.7 (6.9)10.9 (8.7)9.7 (5.4)Mean (SD) urinary sodium:creatinine ratio
0024Missing data
Mean (SD) surgery measured blood pressure (mmHg):
152.9 (13.6)153.8 (15.5)152.4 (14.3)152.9 (15.1)Systolic
89.5 (10.1)89.7 (11.6)89.9 (11.3)92.1 (11.5)Diastolic
Mean (SD) daytime ambulatory blood pressure (mm
Hg):
144.4 (9.0)147.8 (11.7)146.2 (10.5)146.2 (10.6)Systolic
83.5 (9.1)83.6 (8.7)85.4 (9.6)87.1 (10.0)Diastolic
Hospital anxiety and depression scale32:
6.1 (3.8)5.7 (2.9)5.1 (3.6)5.0 (2.9)Mean (SD) anxiety score
3.6 (2.6)3.2 (2.6)2.9 (2.5)2.8 (2.4)Mean (SD) depression score
0022Missing data
7.6 (3.0)7.8 (2.9)Mean (SD) exercise tolerance score48
21Missing data
8.5 (1.4)8.7 (1.4)
Mean (SD) Stanford self efficacy questionnaire (short
version)49
16Missing data
Morisky medication adherence scale50:
63 (31)61 (31)Sometimes forgets to take drugs
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Table 1 (continued)
Primary outcome data not providedPrimary outcome data provided
Variables
Usual care group
(n-24)
Monitored group
(n=18)Usual care group (n=201)Monitored group (n=200)
132 (66)132 (66)Does not forget to take drugs
76Missing data
23 (11)24 (12)Sometimes careless about taking drugs
173 (86)169 (85)Not careless about taking drugs
75Missing data
15 (7)11 (6)Sometimes stops taking drugs when feeling better
180 (90)181 (91)Does not stop taking drugs when feeling better
86Missing data
22 (11)18 (9)Sometimes stops taking drugs when feeling worse
173 (86)170 (85)Does not stop taking drugs when feeling worse
126Missing data
1.7 (1-3)1.5 (1-3)
Median (interquartile range) No of defined daily doses
of hypertensive drugs
0.857 (0.220)0.875 (0.177)Mean (SD) EuroQol-5D22
65Missing data
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Table 2| Daytime ambulatory systolic and diastolic blood pressures over course of study in 359 participants with complete primary outcome
data
P value
Adjusted only for baseline
difference (usual
care−monitored) (95% CI)P value
Adjusted difference*
(usual care−monitored)
(95% CI)
Mean (SD) blood pressure (mm Hg)
Blood pressure
measurement 6 monthsBaseline
Systolic:
0.00064.08 (1.77 to 6.39)0.00024.27 (2.01 to 6.53)140.0 (11.3)146.0 (10.5)Monitored
144.3 (13.4)146.5 (10.7)Usual care
Diastolic:
0.00222.17 (0.79 to 3.56)0.0012.3 (0.92 to 3.61)83.4 (9.1)87.4 (10.1)Monitored
84.3 (10.4)85.7 (9.6)Usual care
*Adjusted difference between treatment groups for baseline blood pressure and minimisation factors.
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Table 3| Mean of second and third surgery measured systolic and diastolic blood pressures over course of study in 374 participants with
surgery measured blood pressure results
P value
Adjusted only for baseline
difference (usual
care−monitored) (95% CI)P value
Adjusted difference* (usual
care−monitored) (95% CI)
Mean (SD) blood pressure (mmHg)
Blood pressure
measurement 6 monthsBaseline
Systolic:
0.0044.31 (1.38 to 7.23)0.00174.63 (1.74 to 7.51)144.7 (16.1)153.1 (15.2)Monitored
148.8 (14.7)152.5 (14.5)Usual care
Diastolic:
0.00242.82 (1.00 to 4.64)0.00212.83 (1.03 to 4.63)86.9 (11.8)92.4 (11.6)Monitored
88.3 (11.2)90.1 (11.4)Usual care
*Adjusted difference between treatment groups for baseline blood pressure and minimisation factors.
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Table 4| Results at six month follow-up. Values are numbers (percentages) unless stated otherwise
P value
Adjusted difference
(95% CI)Usual care group (n=201)Monitored group (n=200)Variables
0.7910.03 (−0.26 to 0.20)30.4 (6.2)30.2 (5.9)Mean (SD) body mass index (kg/m2)
167Missing data
018 (9)22 (11)Smoker
013.6 (8.7)16.0 (8.4)Mean (SD) No of cigarettes/day
0164 (82)172 (86)Non-smoker
0196Missing data
0159 (79)158 (79)Consumes alcohol
02.0 (0.7-4.0)1.7 (0.9-2.9)Median (interquartile range) units of alcohol (10 mL)/day
041 (20)37 (19)Does not consume alcohol
15Missing data
Exhaled carbon monoxide category (parts per million):
0159 (79)171 (86)Non-smoker (1-6)
04 (2)2 (1)Light smoker (7-10)
09 (4)5 (3)Moderate smoker (11-20)
09 (4)16 (8)Heavy smoker (≥20)
206Missing data
0.8550.02 (−0.15 to 0.18)5.3 (1.0)5.5 (1.2)Mean (SD) cholesterol level (mmol/L)
3528Missing data
0.3860.28 (−0.35 to 0.92)37.4 (5.1)38.2 (6.6)Mean (SD) haemoglobin A1c level (mmol/mol)
3932Missing data
0.2280.82 (−0.51 to 2.15)10.6 (7.1)9.5 (6.1)Mean (SD) urinary sodium:creatinine ratio
02427Missing data
Hospital anxiety and depression scale32:
04.8 (3.8)4.8 (3.4)Mean (SD) anxiety score
03.1 (2.9)2.9 (2.8)Mean (SD) depression score
01910Missing data
07.2 (3.0)7.5 (3.0)Mean (SD) exercise tolerance score48
01910Missing data
08.3 (1.8)8.6 (1.5)Mean (SD) Stanford self efficacy questionnaire (short version)49
02317Missing data
0Morisky medication adherence scale50:
055 (27)54 (27)Sometimes forgets to take drugs
0118 (59)137 (69)Does not forget to take drugs
089Missing data
017 (8)16 (8)Sometimes careless about taking drugs
0156 (78)175 (88)Not careless about taking drugs
0289Missing data
09 (4)11 (6)Sometimes stops taking drugs when feeling better
0163 (81)179 (90)Does not stop taking drugs when feeling better
02910Missing data
015 (7)11 (6)Sometimes stops taking drugs when feeling worse
0180 (90)181 (91)Does not stop taking drugs when feeling worse
068Missing data
01.7 (1-3)2.0 (1-3)
Median (interquartile range) No of defined daily doses of
antihypertensive drugs
031Missing data
00.824 (0.178)0.864 (0.185)Mean (SD) EuroQol-5D
02311Missing data
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Table 5| Change in hypertensive drug use at follow-up. Values are number (percentage) unless stated otherwise
P valueUsual care (n=201)Monitored group (n=200)Change in hypertensive drug use from baseline
<0.000111 (5)11 (6)Decrease
149 (74)108 (54)None
26 (13)75 (38)Increase
15 (7)6 (3)Missing data
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Table 6| Patterns of antihypertensive drug group prescribing for patients with primary outcome data
No (%) of patients with change in DDD from baseline to follow-upNo (%) of patients prescribed drug category
Drug category IncreasedSameDecreasedFollow-upBaseline
Thiazides:
7 (4)166 (94)4 (2)78 (44)75 (42)Usual care
18 (10)160 (88)4 (2)85 (47)71 (39)Monitored
β blockers:
4 (2)171 (97)2 (1)31 (18)29 (16)Usual care
3 (2)177 (97)2 (1)34 (19)32 (18)Monitored
ACE inhibitors:
7 (4)171 (97)5 (3)67 (38)71 (40)Usual care
12 (7)156 (86)4 (2)98 (54)81 (45)Monitored
Angiotensin receptor blockers:
7 (4)169 (95)1 (1)37 (21)31 (18)Usual care
12 (7)169 (93)1 (1)36 (20)25 (14)Monitored
Calcium channel blockers:
8 (5)167 (94)2 (1)64 (36)58 (33)Usual care
32 (18)148 (81)2 (1)80 (44)52 (29)Monitored
Diuretics:
0 (0)176 (99)1 (1)2 (1)3 (2)Usual care
4 (2)178 (98)0 (0)10 (5)7 (4)Monitored
α blockers:
3 (2)173 (98)1 (1)18 (10)16 (9)Usual care
6 (3)175 (96)1 (1)13 (7)7 (4)Monitored
Others:
0 (0)177 (100)0 (0)4 (2)4 (2)Usual care
3 (2)178 (98)1 (1)5 (3)4 (2)Monitored
DDD=defined daily dose; ACE=angiotensin converting enzyme.
Data were missing for 24 of 201 (12%) in usual care group and 18 of 200 (9%) in monitored group.
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Table 7| Results from resource use survey
P valueMean difference (95% CI*)Usual care group (n=177)Monitored group (n=177)Resources
General practitioner consultations
In the surgery:
00460648Total No
00140 (79)163 (92)No (%) with ≥1 consultations
0.00021.06 (0.53 to 1.61)2.60 (2.52)3.66 (2.67)Mean (SD)*
<0.000102 (1-4)3 (2-5)Median (interquartile range)†
By telephone:
007787Total No
0043 (24)51 (29)No (%) with ≥1 consultations
0.57420.07 (−0.16 to 0.27)0.44 (1.02)0.49 (0.96)Mean (SD)*
0.335800 (0-0)0 (0-1)Median (interquartile range)†
At home:
001310Total No
007 (4)7 (4)No (%) with ≥1 consultations
Practice nurse consultations
In the surgery:
00229331Total No
00112 (63)116 (66)No (%) with ≥1 consultations
0.01100.58 (0.14 to 1.04)1.29 (1.73)1.87 (2.54)Mean (SD)*
0.053501 (0-2)1 (0-3)Median (interquartile range)†
By telephone:
0017112Total No
0013 (7)54 (31)No (%) with ≥1 consultations
<0.00010.54 (0.36 to 0.72)0.10 (0.38)0.63 (1.17)Mean (SD)*
<0.000100 (0-0)0 (0-1)Median (interquartile range)†
At home:
0013Total No
001 (1)2 (1)No (%) with ≥1 consultations
District nurse consultations
00281Total No
003 (2)1 (1)No (%) with ≥1 consultations
NHS 24 consultations
00712Total No
007 (4)10 (6)No (%) with ≥1 consultations
LUCS consultations
0058Total No
004 (2)8 (5)No (%) with ≥1 consultations
Accident and emergency visits
001410Total No
0010 (6)9 (5)No (%) with ≥1 consultations
Hospital admissions
001521Total No
0011 (6)13 (7)No (%) with ≥1 consultations
LUCS=Lothian Unscheduled Care Service.
*Confidence interval and P value (two tailed) for difference in means estimated by bootstrap (10 000 replications).
†Wilcoxon rank sum test for difference in distribution.
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Figures
Fig 1 Flow of participants through trial. ABPM=ambulatory blood pressure monitoring
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Fig 2 Subgroup analyses on primary outcome of average daytime ambulatory systolic blood pressure measured at six
months
Fig 3 Number of antihypertensive drugs by randomised group and follow-up point
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